Synergistic Antiandrogenic Effects of Topical Combinations of 5Α

Total Page:16

File Type:pdf, Size:1020Kb

Synergistic Antiandrogenic Effects of Topical Combinations of 5Α Synergistic ·Antiandrogenic Effects of Topical Combinations of Sa-Reductase and Androgen Receptor Inhibitors in the Hamster Sebaceous Glands Jonathan R. Matias, M.S., Virginia L. Malloy, M.S., and Norm.an Orentreich, M.D. Biomedical Research Station, Orcntreich Foundation for the Advancement of Science, Inc., Cold Spring-on-Hudson, New York ORM, VLM, NO), and Department of Dermatology, NYU School of Medicine, New York, New York U.S.A. (NO) The androgenic action of dihydrotestosterone (DHT) is an­ produced any effect on SGS. When combinations of these tagonized by agents that compete with testosterone for the two steroids were applied at low concentrations, SGS de­ Sa-reductase enzyme and by agents that block the binding of creased unilaterally to approximately SO%. This synergy oc­ DHT to its receptor. The topical synergistic effect of Sa-re­ curred best at a P : SL ratio of 1 : 2. The lower effective con­ ductase (SaRI) and androgen receptor inhibitors (ARI) was centrations of P may be explained by its greater percutaneous determined by measurement of the sebaceous gland size absorption. Synergy was also demonstrated at low concen­ (SGS) of the ventral ear skin of the intact, sexuall y mature trations with other antiandrogens: cyproterOlle acetate, can­ male Syrian hamsters. Progesterone (P), a SaRI, and spiro­ renone, hydroxyflutamide, and N -N-diethyl-4-methyl- nolac tone (SL), an ARI, produced a dose responsive decrease 3-oxo-4-aza-5a-androstane-17,B-carboxamide. The use of in SGS at topical concentrations of 0.01 % to 5.0%. At con­ anti-androgen combinations at low concentrations is of value centrations of 1,3, and 5%, P and SL combinations produced because of the decreased risk of systemic side effects while neither an additive nor synergistic inhibition ofSGS. At very maintaining potent topical efficacy. ] Jil l/est Dermatol low concentrations of up to 0.10%, neither P nor SL alone 91:429-433,1988. ntiandrogens are divided into two major classes. The each class. In this study the androgen-sensitive sebaceous glands of first is represented by Sa-reductase inhibitors (SaRI), the hamster ventral ear pinna were utilized as a target organ for which co mpete with testosterone for the binding site evaluating the effect of topically applied combinations of antian­ in the Sa-reducta se enzyme. The second group is drogens. W e report here that combinations of topically applied comprised of androgen receptor inhibitors (ARI), SaRI and ARI exert a potent synergistic effect at very low doses Aw hich interf ere with the binding of dihydrotestosterone (DHT) to without evidence of sys temic side effects. the androgen receptor protein . Details of the biochemical and phys­ iologic effects of antiandrogens can be found in numerous reviews MATERIALS AND METHODS [e.g. , Refs 1,2). Animals Male Syrian golden hamsters were purchased from Har­ Because both types of antiandrogens act through entirely differ­ lan-Sprag ue Dawley, Inc. (Farmersburg, IN), at 10-11 weeks of ent mechanisms, the overall effi cacy of antiandrogen therapy might age. The animals werc houscd at a density of 4 to 5 animals per cage be enhanced by using combinations of selected compounds from with a photoperiod of 14 h li ght and 10 h dark. Food and water were provided ad libitum. The hamsters were acclimated to the labora­ tory conditions for at leas t 1 week prior to the experiments. Manuscript received N ovember 3, 1987; accepted for publication April Chemicals The following were purchased commerciall y: spiron­ 2 1,1988. Reprint requ ests to: Jonathan R. Matias, Biomedical Research Station, olactone (SL) from Sigma C hemical Company (St. Louis, MO); Orentreich Foundation for the Advancement of Scicncc, Inc., RD 2, Box progesterone (P) from Upjohn Company (Kalamazoo, MI); 4-preg­ 375, Cold Spring-on-Hudso n, NY 10516. ncne-3-one (4P3) fro m SyntBiotech, Inc. (Ncw York, NY); desox­ Abbreviations: ycorticosterone acetate (DOCA) , medroxyproges terone acetate ARI: androgen receptor inhibitor (MPA) and 4-androsten-3-one-17p-ca rboxylic acid (1 7BCA) fro m CN: ca nrcnone Steral oids (Wilton, NH). The following compounds were received 17 PCA: 4-androstcn-3-onc-17P carboxylic acid as gifts: canrenone (C N) from G.D. Searle Company (Skokie, IL); CA: cy proterone acetate n,n dicthyl-4 methyl-3-oxo-4-aza-Sa-androstanc 17p-carboxa­ DHT: dihydrotcstostcronc lI1ide (4-MA) from Merck, Sharpe, and Dohme (Rahway, NJ); hy­ DOCA: desoxycorticosterone acetate HF: hydroxyfluta111id e droxyflutamide (HF) and cy proterone acctatc (CA) from Schering 4MA: 1l,Il-di ethyl-4 1l1cthyl- 3-oxo-4-aza-Sa-androstanc 17p-carboxa- AG (Berlin, West Germany). 111 ide Radiolabeled steroids were obtained from th e following sources: MPA: 111 edroxyprogcstcronc acetate [1,2-3H(N))-progesterone (S.A. 57.5 CI/l11mol) from New En­ P: Progesterone gland Nuclea r (B os ton, MA); [1 ,2-3H (N))-spironolac tone (S.A. 44 4P3: 4-prcgnene-3-one Ci/ mmol) fro m Amersham (Arlington Heights, IL). 5 RI : Sa-rcductase inhibitor SL: spiro nolactone Procedures for the Topical Study The antiandrogens were dis­ SGS: sebaceous gland size solved in acctone either separately or in combinations. Twenty-five 0022-202X/88/S03.50 Copyright © 1988 by The Society for Investiga tive Dcrmatology, Inc. 429 430 MATIAS, MALLOY, AND ORENTREICH THE JOURNAL OF INVESTIGATIVE DERMATOLOGy microliters of each solution was applied with a micropipette on the ventral surface of the right ear pinna, once in the morning and once - \00 ~ in the afternoon of each day, Monday through Friday. The left ;§ 80 pinna of the same animal was not treated and served as an indicator '0 60 of any systemic effect of the antiandrogen treatment. Control ani­ ~ w 40 ~ N PROGES TERON E mals received topical applications of acetone alone to the right ;;;; 20 pinna. Unless otherwise specified, the treatments were terminated <=>z « after 4 weeks and the animals were killed by cervical dislocation. A -' '"" \00 -- ·-"O"-- -- --o--~ __o.., preliminary study indicated that chis was the minimum time for ' . :=>'" 0 80 b attaining an antiandrogenic response in intact mature males. ~ <D 60 The method used for evaluating the sebaceous gland response was W previously described in detail (3,4]. Briefly, the ear was cut at the cr'" 40 :5 SPIRONOLACTO N E proximal base with scissors, and the ventral ear skin, rich in seba­ 20 ceous glands, was manually separated from the cartilage. The skin was immediately stained for 3h with 0.1 % (w Iv) solution of Sudan 0 0. 1 I 10 Black B in propylene glycol. The ear skin was then fixed in 10% % CO NCE NTRATI ON buffered formalin after an overnight rinse in a solution of propylene Figure 1. Dose-dependent inhibitory effect of P and SL on the sebaceous glycol:water (85:15). A 2-mm punch biopsy of the medial zone (an glands of male Syrian hamsters (N=5-6 animals per data point). (e): area 5-8 mm from the apex of the pinna along the midline) was treated;(o): contralateral untreated. obtained. The whole-mount preparation of the ventral pinna was viewed from the dermal side at a magnification of 150X using an Ortholux low doses, i.e., doses of 0.1 % or lower. However, a marked syner, II microscope equipped with a drawing attachment (Leitz). The size gistic inhibition, particularly at the lowest dose (Exp. B, Table II), of each sebaceous gland unit was quantitated planimetrically using a was evident when P and SL were combined. When applied togethet computerized graphics calculator (Numonics Corp., Lansdale, PA). at a concentration of 0.025% for P and 0.05% for SL, the sebaceous Procedure for the Evaluation of Percutaneous Absorption gland size decreased to 58% of the control value. It is also important to note that the systemic side effects did not occur at such lo\\> The penetration rate of P and SL through the skin was determined concentrations (see Fig 1). This experiment was repeated two mor ~ by measuring the urinary excretion of each steroid according to the times and showed the same synergistic antiandrogenic effect. Fur, method of Feldmann and Maibach [5] . The radiolabeled steroid (0.5 therdilution of the 0.025% P and 0.05% SL combination resulted ill. .uCi) was dissolved in acetone with 4 .ug of unlabeled carrier, in a eventual loss of the antiandrogenic effect (Table III). total volume of 10.u1. After applying the solution on the ventral ear Different ratios of P and SL combinations at low concentrations pinna, the hamster was placed inside a plastic metabolic cage (Nal­ were also tested to determine the combination that would produce gene). Urine was collected daily for 5 d. An aliquot of urine was the optimal synergistic effect. As can be seen in Fig 2, synergisnl counted in a scintillation counter (Packard TriCarb) using 3H-tolu­ occurred best at a P:SL ratio of 1:2. To test whether this ratio was ene as the internal standard. The values were corrected for incom­ related to the penetration rates of these steroids through the skin, plete urinary excretion as described previously [5]. radiolabeled P and SL were applied to the ventral ear skin and the Calculation of the Index of Synergism or Antagonism To rate of percutaneous absorption was measured. The data (Table IV) determine whether or not a synergistic, antagonistic, or additive indicated that P was absorbed at twice the rate observed for SL. effect was present for each combination, an index was calculated as Synergistic effects were also demonstrated for other potent follows: lndex = (1 - D/c)/(1 - Alc) + (1 - Blc), where A is SaRI's, such as 4MA and 4P3, when used in combination with SL the mean value calculated for SaRI treated hamsters; B is the mean (Table V, experiments A and B).
Recommended publications
  • Compositions Comprising Drospirenone Molecularly
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Downloaded 9/24/2021 7:05:26 PM
    Environmental Science Processes & Impacts PAPER View Article Online View Journal | View Issue Solid-phase extraction as sample preparation of water samples for cell-based and other in vitro Cite this: Environ. Sci.: Processes Impacts,2018,20,493 bioassays† a bc d b Peta A. Neale, Werner Brack, Selim A¨ıt-A¨ıssa, Wibke Busch, ef b d Juliane Hollender, Martin Krauss, Emmanuelle Maillot-Marechal,´ Nicole A. Munz,ef Rita Schlichting,b Tobias Schulze, b Bernadette Voglere and Beate I. Escher *abg In vitro bioassays are increasingly used for water quality monitoring. Surface water samples often need to be enriched to observe an effect and solid-phase extraction (SPE) is commonly applied for this purpose. The applied methods are typically optimised for the recovery of target chemicals and not for effect recovery for bioassays. A review of the few studies that have evaluated SPE recovery for bioassays showed a lack of experimentally determined recoveries. Therefore, we systematically measured effect recovery of a mixture of 579 organic chemicals covering a wide range of physicochemical properties that were spiked into a pristine water sample and extracted using large volume solid-phase extraction (LVSPE). Assays indicative of activation of xenobiotic metabolism, hormone receptor-mediated effects and adaptive stress responses were applied, with non-specificeffects determined through cytotoxicity measurements. Overall, effect recovery was found to be similar to chemical recovery for the majority of bioassays and LVSPE blanks had no effect. Multi-layer SPE exhibited greater recovery of spiked chemicals compared to LVSPE, but the blanks triggered cytotoxicity at high enrichment. Chemical recovery data together with single chemical effect data were used to retrospectively estimate with reverse recovery modelling that there was typically Received 19th November 2017 less than 30% effect loss expected due to reduced SPE recovery in published surface water monitoring Accepted 15th February 2018 studies.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Cyproterone Acetate Or Spironolactone in Lowering Testosterone Concentrations for Transgender Individuals Receiving Oestradiol Therapy
    ID: 19-0272 8 7 L Angus et al. Anti-androgens in 8:7 935–940 transfeminine individuals RESEARCH Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy Lachlan Angus1, Shalem Leemaqz2, Olivia Ooi1, Pauline Cundill3, Nicholas Silberstein3, Peter Locke3, Jeffrey D Zajac1 and Ada S Cheung1 1Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia 2Robinson Research Institute, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia 3Equinox Gender Diverse Clinic, Thorne Harbour Health, Fitzroy, Victoria, Australia Correspondence should be addressed to A S Cheung: [email protected] Abstract Background: Oestradiol with or without an anti-androgen (cyproterone acetate or Key Words spironolactone) is commonly prescribed in transfeminine individuals who have not had f transgender persons orchidectomy; however, there is no evidence to guide optimal treatment choice. f transsexualism Objective: We aimed to compare add-on cyproterone acetate versus spironolactone in f gender identity lowering endogenous testosterone concentrations in transfeminine individuals. f gender dysphoria Design: Retrospective cross-sectional study. f androgens Methods: We analysed 114 transfeminine individuals who had been on oestradiol therapy for >6 months in two gender clinics in Melbourne, Australia. Total testosterone concentrations were compared between three groups; oestradiol alone (n = 21), oestradiol plus cyproterone acetate (n = 21) and oestradiol plus spironolactone (n = 38). Secondary outcomes included serum oestradiol concentration, oestradiol valerate dose, blood pressure, serum potassium, urea and creatinine. Results: Median age was 27.0 years (22.5–45.1) and median duration of hormone therapy was 1.5 years (0.9–2.6), which was not different between groups.
    [Show full text]
  • Determination of Spironolactone and Canrenone in Human Plasma by High-Performance Liquid Chromatography with Mass Spectrometry Detection†
    CROATICA CHEMICA ACTA CCACAA, ISSN 0011-1643, e-ISSN 1334-417X Croat. Chem. Acta 84 (3) (2011) 361–366. CCA-3483 Original Scientific Article Determination of Spironolactone and Canrenone in Human Plasma by High-performance Liquid Chromatography with † Mass Spectrometry Detection Laurian Vlase,a Silvia Imre,b,* Dana Muntean,a Marcela Achim,a and Daniela-Lucia Munteanb aDepartment of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, University of Medicine and Pharmacy “Iuliu Haţieganu”, Victor Babeş street 8, RO-400012, Cluj-Napoca, Romania bDepartment of Drug Analysis, Faculty of Pharmacy, University of Medicine and Pharmacy, Gheorghe Marinescu street 38, RO-540139, Târgu-Mureş, Romania RECEIVED SEPTEMBER 30, 2010; REVISED DECEMBER 21, 2010; ACCEPTED JANUARY 17, 2011 Abstract. A new simple, sensitive and LC-MS/MS method for quantification of spironolactone and its me- tabolite, canrenone, in human plasma is proposed. The analytes were analysed on a C18 column at 48 ºC, by using a mobile phase of 58 % methanol, 42 % 10 mmol dm−3 ammonim acetate in water and a flow rate of 1 mL/min. The detection of both analytes in plasma was performed as follows: ESI+, EIC (m/z 169;187;283;305) from m/z 341, after protein precipitation with methanol. Calibration curves were gener- ated over the ranges 2.77–184.50 ng/mL for spironolactone and 2.69–179.20 ng/mL for canrenone by us- ing a weighted (1/y) linear regression. The absolute values of within- and between-run precision and accu- racy for both analytes ranged between 3.1 and 13.9 %, and the mean recovery was 99.7 %.
    [Show full text]
  • Clinical Efficacy of Potassium Canreonate
    Dąbrowski et al. Trials (2020) 21:397 https://doi.org/10.1186/s13063-020-04277-3 STUDY PROTOCOL Open Access Clinical efficacy of potassium canreonate- canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN- AF trial) Rafał Dąbrowski*, Paweł Syska, Justyna Mączyńska, Michał Farkowski, Stefan Sawicki, Agata Kubaszek-Kornatowska, Piotr Michałek, Ilona Kowalik, Hanna Szwed and Tomasz Hryniewiecki Abstract Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration. Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2–3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration.
    [Show full text]
  • Pairwise Comparisons
    National Institute for Health and Care Excellence Final Acne vulgaris: management [E2] Management options for mild to moderate acne – pairwise comparisons NG198 Evidence review underpinning recommendations 1.5.1, 1.5.2 and 1.5.5 to 1.5.14 (excluding 1.5.6 which is underpinned by evidence review L, 1.5.10 and bullet points 2 and 3 of recommendation 1.5.12 which are underpinned by evidence review F1 and 3 research recommendations in the NICE guideline - see evidence review E1 for the committee’s discussion of the evidence) June 2021 Final These evidence reviews were developed by the National Guideline Alliance which is a part of the Royal College of Obstetricians and Gynaecologists FINAL Error! No text of specified style in document. Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Aldactone® Spironolactone Tablets, USP
    NDA 12-151/S-062 Page 2 Aldactone® spironolactone tablets, USP WARNING Aldactone has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions). Aldactone should be used only in those conditions described under Indications and Usage. Unnecessary use of this drug should be avoided. DESCRIPTION Aldactone oral tablets contain 25 mg, 50 mg, or 100 mg of the aldosterone antagonist spironolactone, 17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone acetate, which has the following structural formula: Spironolactone is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform. Inactive ingredients include calcium sulfate, corn starch, flavor, hypromellose, iron oxide, magnesium stearate, polyethylene glycol, povidone, and titanium dioxide. ACTIONS / CLINICAL PHARMACOLOGY Mechanism of action: Aldactone (spironolactone) is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Aldactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Aldactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone antagonist activity: Increased levels of the mineralocorticoid, aldosterone, are present in primary and secondary hyperaldosteronism. Edematous states in which secondary aldosteronism is usually involved include congestive heart failure, hepatic cirrhosis, and the nephrotic syndrome. By competing with aldosterone for receptor sites, Aldactone provides effective therapy for the edema and ascites in those conditions.
    [Show full text]
  • 2019 Prohibited List
    THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2019 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2019 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES Mestanolone; S0 Mesterolone; Any pharmacological substance which is not Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- addressed by any of the subsequent sections of the 3-one); List and with no current approval by any governmental Metenolone; regulatory health authority for human therapeutic use Methandriol; (e.g. drugs under pre-clinical or clinical development Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- or discontinued, designer drugs, substances approved androstan-3-one); only for veterinary use) is prohibited at all times. Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); ANABOLIC AGENTS Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- S1 androst-1-en-3-one); Anabolic agents are prohibited. Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); 1. ANABOLIC ANDROGENIC STEROIDS (AAS) Methyltestosterone; a. Exogenous*
    [Show full text]